Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | ELANE | P08246 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.42 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.42 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL593272 | 0.94 | CYP19A1 (0.58) | CYP19A1ALDH1A1ELANEKMT2AHPGD | |
| SCHEMBL27396289 | 0.91 | CYP19A1 (0.56) | CYP19A1ALDH1A1ELANEKMT2AHPGD | |
| SCHEMBL1931453 | 0.82 | KMT2A (0.54) | CYP19A1ALDH1A1RAB9AELANEKMT2A | |
| SCHEMBL7564565 | 0.82 | ASAH1 (0.55) | CYP19A1ALDH1A1ELANEKMT2AMEN1 | |
| SCHEMBL3404040 | 0.79 | PPARG (0.54) | CYP19A1ELANEKMT2AHPGDL3MBTL1 | |
| Cyclohexane SCHEMBL23214149 | 0.78 | ALDH1A1 (0.53) | ALDH1A1RAB9AELANEKMT2AHPGD | |
| Cyclohexane SCHEMBL6263406 | 0.78 | ALDH1A1 (0.53) | ALDH1A1RAB9AELANEKMT2AHPGD | |
| SCHEMBL153387 | 0.78 | CYP19A1 (0.55) | CYP19A1ALDH1A1RAB9AELANEKMT2A | |
| SCHEMBL43742 | 0.78 | KMT2A (0.61) | CYP19A1ALDH1A1ELANEKMT2AHPGD | |
| SCHEMBL538524 | 0.77 | CYP19A1 (0.76) | CYP19A1ALDH1A1KMT2AHPGDL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1620083-A2 | COMBINATION THERAPIES | Pharmacia & Upjohn Company LLC (US) | 2006-02-01 | — | — | EP | disclosed |
| US-6946486-B2 | Quaternary ammonium compounds | PHARMACIA & UPJOHN CO. (US) | 2005-09-20 | — | — | US | disclosed |
| EP-1558563-A1 | QUATERNARY AMMONIUM COMPOUNDS | Pharmacia & Upjohn Company LLC (US) | 2005-08-03 | — | — | EP | disclosed |
| US-20040220224-A1 | Method of treating irritable bowel syndrome | PFIZER INC | 2004-11-04 | — | — | US | disclosed |
| WO-2004091596-A2 | COMBINATION THERAPIES FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-10-28 | — | — | WO | disclosed |
| WO-2004091597-A2 | METHOD OF TREATING IRRITABLE BOWEL SYNDROME (IBS) | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-10-28 | — | — | WO | disclosed |
| US-20040209916-A1 | Combination therapies | PFIZER INC | 2004-10-21 | — | — | US | disclosed |
| US-20040116519-A1 | Quaternary ammonium compounds | PHARMACIA & UPJOHN COMPANY | 2004-06-17 | — | — | US | disclosed |
| WO-2004039763-A1 | QUATERNARY AMMONIUM COMPOUNDS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-05-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209916-A1 | Combination therapies | ADRA2C, ADRB2, ADRA2A | CYP19A1 1295/4885ALDH1A1 1063/4885RAB9A 817/4885 |
| US-20040220224-A1 | Method of treating irritable bowel syndrome | SI, VIP, SLC10A2 | CYP19A1 3089/4885ALDH1A1 2507/4885RAB9A 1733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.